The South & Central America infectious disease diagnostics market was valued at US$1.54 billion in 2022 and is expected to reach US$2.46 billion by 2030; it is estimated to grow at a CAGR of 6.0% from 2022 to 2030.
Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential to reduce economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally to detect animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, susceptible, and specific, with the ability to detect at a high volume.
Even though conventional virological methods are incredibly reliable, they are time-consuming and labor-intensive procedures. Lateral flow and enzyme-linked immunosorbent assay can be used for rapid detection. Multiplex bead immuno or Luminex assay is a fluorescent beads-based high-throughput quantitative technique used for the detection of multiple antibodies specific for different infectious diseases at the same time in a single reaction, leading to more rapid, economical, and accurate results compared with conventional ELISA. In addition, the protein chip based on surface plasmon resonance (SPR) appears to be a rapid valuable tool in the sero-diagnosis of infection or antibody titration. Recombinant antibodies can also be produced in heterologous systems by using rDNA technology and used for developing diagnostic tests.
Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating African swine fever virus, classical swine fever virus, avian influenza virus, and foot-and-mouth disease virus for research purposes. Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR. Thus, diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals is fueling the diagnostics in veterinary diagnosis.
Based on product, the South & Central America infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held the largest share in 2022.
By technology, the South & Central America infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The molecular-based diagnostic techniques segment held the largest share in 2022. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.
By application type, the South & Central America infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held a larger share in 2022.
By testing type, the South & Central America infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held a larger share in 2022. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.
By end user, the South & Central America infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held the largest share in 2022.
Based on country, the South & Central America infectious disease diagnostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the South & Central America infectious disease diagnostics market in 2022.
Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA are some of the leading companies operating in the South & Central America infectious disease diagnostics market.
Rising Application of Diagnostics in Veterinary Infectious Disease Drive South & Central America Infectious Disease Diagnostics Market
Veterinary infectious diseases negatively impact the health of domestic animals, livestock, and wildlife. As a result of intensive animal farming, there are conditions for the emergence and amplification of disease epidemics due to the genetic and physical proximity of the billions of animals, often in frail health, that are raised indoors every year. Moreover, animal farming contributes to the spread of infections from wild animals due to deforestation caused by the expansion of agricultural land use.Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential to reduce economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally to detect animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, susceptible, and specific, with the ability to detect at a high volume.
Even though conventional virological methods are incredibly reliable, they are time-consuming and labor-intensive procedures. Lateral flow and enzyme-linked immunosorbent assay can be used for rapid detection. Multiplex bead immuno or Luminex assay is a fluorescent beads-based high-throughput quantitative technique used for the detection of multiple antibodies specific for different infectious diseases at the same time in a single reaction, leading to more rapid, economical, and accurate results compared with conventional ELISA. In addition, the protein chip based on surface plasmon resonance (SPR) appears to be a rapid valuable tool in the sero-diagnosis of infection or antibody titration. Recombinant antibodies can also be produced in heterologous systems by using rDNA technology and used for developing diagnostic tests.
Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating African swine fever virus, classical swine fever virus, avian influenza virus, and foot-and-mouth disease virus for research purposes. Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR. Thus, diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals is fueling the diagnostics in veterinary diagnosis.
South & Central America Infectious Disease Diagnostics Market Overview
The Rest of South and Central America comprises countries such as Peru, Chile, Bolivia, and Ecuador. The market in these countries is likely to witness growth opportunities owing to the rise in the prevalence of infectious diseases and the increase in healthcare expenditure. In the last decade (2012-2022), the number of HIV infections has risen by nearly 75% in the Rest of South & Central America. According to the data provided by AIDS Healthcare Foundation Chile, in 2019, Chile had 6.720 new HIV infections. Out of the 17 million total population, 71,000 people were living with HIV in 2019. Thus, the increase in the prevalence of HIV in the region is fueling the growth of the market.South & Central America Infectious Disease Diagnostics Market Segmentation
The South & Central America infectious disease diagnostics market is segmented based on product, technology, application type, testing type, end user, and country.Based on product, the South & Central America infectious disease diagnostics market is segmented into kits & reagents, instruments, and software & services. The kits & reagents segment held the largest share in 2022.
By technology, the South & Central America infectious disease diagnostics market is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic techniques, clinical biology, and others. The molecular-based diagnostic techniques segment held the largest share in 2022. The immunodiagnostics segment is further subsegmented into enzyme-linked immunosorbent assay (ELISA), western blotting analysis, and immunofluorescence assay. The molecular-based diagnostic techniques segment is further subsegmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), DNA microarrays, and others.
By application type, the South & Central America infectious disease diagnostics market is bifurcated into laboratory testing and point-of-care testing. The laboratory testing segment held a larger share in 2022.
By testing type, the South & Central America infectious disease diagnostics market is bifurcated into human testing and veterinary testing. The human testing segment held a larger share in 2022. The human testing segment is further subsegmented into HIV, hepatitis, HAIs, HPV, tuberculosis, influenza, and others.
By end user, the South & Central America infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, research institutes, homecare settings, and others. The diagnostic laboratories segment held the largest share in 2022.
Based on country, the South & Central America infectious disease diagnostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the South & Central America infectious disease diagnostics market in 2022.
Abbott Laboratories, Bruker Corp, Cardinal Health Inc, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, ACON Laboratories Inc, and DiaSorin SpA are some of the leading companies operating in the South & Central America infectious disease diagnostics market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. South & Central America Infectious Disease Diagnostics Market - Key Industry Dynamics
5. Infectious Disease Diagnostics Market - South & Central America Market Analysis
6. South & Central America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by Product
7. South & Central America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by Technology
8. South & Central America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by Application Type
9. South & Central America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by Testing Type
10. South & Central America Infectious Disease Diagnostics Market - Revenue and Forecast to 2030 - by End User
11. South & Central America Infectious Disease Diagnostics Market - Country Analysis
12. Industry Landscape
13. Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Bruker Corp
- Cardinal Health Inc
- F. Hoffmann-La Roche Ltd
- Trinity Biotech Plc
- Danaher Corp
- Bio-Rad Laboratories Inc
- ACON Laboratories Inc
- DiaSorin SpA